✦ LIBER ✦

Activity and acceptability of piribedil in Parkinson's disease: a multicentre study

✍ Scribed by P. Rondot; M. Ziegler

Publisher: Springer
Year: 1992
Tongue: English
Weight: 627 KB
Volume: 239
Category: Article
ISSN: 0340-5354
DOI: 10.1007/bf00819564

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A randomized, double-blind study of a sk

A randomized, double-blind study of a skin patch of a dopaminergic agonist, piribedil, in Parkinson's disease

✍ Jean-Louis Montastruc; Marc Ziegler; Olivier Rascol; Muriel Malbezin 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 55 KB 👁 2 views

Early piribedil monotherapy of Parkinson

Early piribedil monotherapy of Parkinson's disease: A planned seven-month report of the REGAIN study

✍ Olivier Rascol; Bruno Dubois; Alexandre Castro Caldas; Stephen Senn; Susanna Del 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 130 KB

## Abstract Piribedil is a D~2~ dopamine agonist, which has been shown to improve symptoms of Parkinson's disease (PD) when combined with L‐dopa. The objective of this study was to compare the efficacy of piribedil monotherapy to placebo in patients with early PD over a 7‐month period. Four hundred

fMRI study of motor cortex activity modu

fMRI study of motor cortex activity modulation in early Parkinson's disease

✍ Marta Moraschi; Giovanni Giulietti; Federico Giove; Manuela Guardati; Girolamo G 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 484 KB

Ethosuximide and tremor in Parkinson's d

Ethosuximide and tremor in Parkinson's disease: A pilot study

✍ E. Pourcher; B. Gomez-Mancilla; Dr. P. J. Bédard 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 376 KB 👁 1 views

## Abstract Following the demonstration of an antitremor effect of ethosuximide in the 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) monkey model, we have tested the effect of this drug in 10 patients with typical parkinsonian tremor. Six patients suffered from Parkinson's disease with promin

Efficacy of piribedil as early combinati

Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: A 6-month, randomized, placebo-controlled study

✍ Marc Ziegler; Alexandre Castro-Caldas; Susanna Del Signore; Olivier Rascol 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 775 KB

## Abstract Piribedil is a non‐ergot D2/D3 agonist with a significant antagonist action on α2A and α2C adrenergic receptor subtypes. This double‐blind placebo‐controlled study was undertaken to confirm the efficacy of 150 mg/day piribedil po in improving motor symptoms of idiopathic Parkinson's dis

Incidence of Parkinson's disease and par

Incidence of Parkinson's disease and parkinsonism in northern Sweden: A population-based study

✍ Jan Linder; Hans Stenlund; Lars Forsgren 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 83 KB 👁 1 views

## Abstract The differential diagnosis of parkinsonian disorders is difficult, especially early in the course of the diseases. The clinical subtypes of Parkinson's disease (PD) have not so far been described in newly diagnosed patients. We present a prospective incidence cohort study of patients wi